Congestive heart failure and converting enzyme inhibition: failure of current prognostic criteria for predicting subsequent renal insufficiency.
Angiotensin-1-converting enzyme inhibitors have an effective and established role in the treatment of patients with congestive heart failure. However, a small number of such patients will subsequently develop renal insufficiency. These patients may be identified prior to, or shortly after, commencement of therapy by recognized criteria. This report describes 4 patients with congestive heart failure who developed severe renal insufficiency secondary to either enalapril or captopril therapy in the absence of any currently recognized predisposing factors. One patient died.
Odum
J
J
Department of Nephrology, North Staffordshire Royal Infirmary, Hartshill, Stoke on Trent, UK.
Carson
P
P
Russell
G
G
D000368:Aged; D002216:Captopril / Q000009:adverse effects* / Q000627:therapeutic use; D000075202:Contraindications; D004656:Enalapril / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged
D004656:Enalapril; D002216:Captopril